REMARKS

Reconsideration of the patentability of applicants' claimed invention is requested respectfully.

Status of the Claims

Claims 1 to 17 and 22 have been cancelled. Claims 18, 20, 21, 23, 25, 26, 29 to 33, and 36 to 38 have been amended. Claims 39 to 45 have been added. Accordingly, there is presented for the Examiner's consideration Claims 18 to 21 and 23 to 45, which total in number 27, of which 5 are in independent form. The total number of claims and of independent claims are less than paid for at the time of the filing of the present application. Accordingly, no claim fee is due.

Summary of the Examiner's Rejections

All of applicants' originally filed claims (Claims 1 to 38) have been rejected.

The present action includes the following rejections:

(A) Claims 1 to 17 and 36 to 38 have been rejected under 35 USC § 102(b) as being anticipated by the disclosure of International Application bearing Publication No. WO 99/02133, dated January 21, 1999;

(B) Claims 1 to 7 have been rejected under 35 USC § 102(b) as being anticipated by the disclosure of International Application bearing Publication No. WO 93/15726, dated August 19, 1993;

(C) Claims 18 to 24 and 26 to 28 have been rejected under 35 USC § 103(a) as being obvious over the disclosure of the aforementioned Lefevre et al. publication in view of the disclosure of U.S. Patent No. 5,350,769 to Kasai et al; and

(D) Claims 25 and 29 to 35 have been rejected under 35 USC § 103(a) as being obvious over the disclosure of the aforementioned Lefevre et al. publication in view of the disclosures of the aforementioned Kasai et al patent and U.S. Patent No. 4,692,329 to Klein et al.

It is requested respectfully that the Examiner withdraw the aforementioned rejections in view of the discussion which follows.

Summary of Applicants' Claimed Invention

Applicants' claims define various embodiments of the present invention.

For example, Claim 18 defines a package which comprises a container for holding a component comprising a benzoyl peroxide (BP) gel and another container for holding a component comprising an erythromycin gel, each of the components being separated one from the other in their respective containers which comprise the package. As explained in the present application and in the prior art, a composition comprising BP and erythromycin is effective in treating acne, but such composition tends to degrade prematurely when the aforementioned constituents are mixed together. The aforementioned package is designed in a manner such that, at the time of use and before premature degradation, the components can be dispensed simultaneously from their respective containers and mixed to form an acne-treating composition which can then be applied promptly (and before degradation) to facial areas of the patient to treat the acne.

As set forth in Claim 18, the package is designed to dispense simultaneously the components from their containers, the viscosities of the components being such that, upon the application of a uniform force to the components, substantially equal volumes of the components are dispensed from their respective containers.

Claim 36, which is dependent on Claim 18 defines a "multiple use" package which is capable of holding, in their respective containers, the components in amounts which comprise

multiple doses that can be dispensed from the package in single dose form (see the present application, page 15, beginning at line 11 and continuing to the end of page 20).

Claim 38 defines a "single-dose package" which can be thrown away after its contents are emptied (see the present application, page 12, beginning at line 15 and continuing to page 14, lines 1 to 26).

In another embodiment of the present invention, Claim 23 defines a composition which is suitable for the treatment of acne and comprises BP, erythromycin, and, as a gelling (thickening) agent, hydroxylpropylcellulose, which is disclosed in the present application as being a highly preferred gelling agent (see page 30, lines 12 and 13).

The following discussion will explain how applicants' claims distinguish over the prior art and why they are considered to define patentable subject matter.

Summary of the Disclosures of the References

There follows a summary of each of the cited references in the context of the relationship of applicants' claimed subject matter to the disclosures of the references.

The Lefevre et al. Publication

The Lefevre et al. publication discloses broadly a multi-compartment dispensing system in which a composition comprising BP is held in one compartment and separated from a second pharmaceutically active ingredient held in another compartment, the BP typically affecting adversely the chemical stability of the second pharmaceutically active ingredient in a composition comprising these constituents. The mixing of the constituents can occur in either *in situ* or in the dispensing system just prior to delivery.

The Lefevre et al. publication discloses various pharmaceutically active ingredients that can be combined with BP including, for example, anti-microbial agents such as anti-bacterial or anti-fungal agents, for example, erythromycin, natamycin, clindamycin, lincomycin, sphingosine and phytosphingosine. This reference makes clear that the nature of the form in the dispensing system of each of the compositions comprising the BP and the second active ingredient is dependent on the particular ingredients involved and the desired properties of the composition comprising the BP and second active ingredient. This is spelled out, for example, in the following paragraph which appears in the reference.

> Thus, the nature of the first and second composition are determined by on the one hand the stability requirements of each individual active ingredient and on the other hand the desired properties of the final composition. (page 3, lines 13 to 16).

Consistent with the above disclosure, the Lefevre et al. publication discloses that a stable BP composition is formulated as a suspension in which BP particles are maintained in suspension by the use of: (A) a thickening agent which is incorporated in a formulation comprising BP particles and which keeps the particles from settling; and (B) a vehicle in which the BP particles have a relatively low solubility (see the reference, page 3, lines 29 to 35 and page 8, lines 23 to 34). Similarly, Lefevre et al. refer to stable natamycin compositions which are in the form of suspensions of natamycin crystals in an aqueous medium which contains a thickening agent to prevent sedimentation of the crystals.

In distinct contrast to the Lefevre et al. teachings that stable BP and natamycin compositions need to be in the form of thickened suspensions, Lefevre et al. teach explicitly that stable compositions of other types of active ingredients, including specifically erythromycin, are obtained by preparing a solution thereof in which the erythromycin (or other active ingredient) is dissolved in a high concentration of a non-aqueous solvent for the active ingredient (see, for example, the reference, page 5, lines 15 to 29; page 6, lines 16 to 29; and the paragraph bridging pages 8 and 9 which refer to a concentrated alcoholic clear solution of erythromycin). Similarly, Lefevre et al. refer to stable clindamycin compositions which are in the form of a solution (please

see Appendix A hereof which consists of a copy of "Aqueous Stability of Clindamycin, T.O. Oesterling, *Journal of Pharmaceutical Sciences*, Vol. 59, No. 1, January 1970" by T. O. Oesterling which is referred to in the reference in the paragraph bridging pages 5 and 6).

As discussed more fully below, applicants' claims distinguish over the Lefevre et al. disclosure in various ways, including defining the erythromycin-containing composition as being in the form of a gel.

The Baroody et al. Publication

This reference discloses acne-treating compositions comprising benzoyl peroxide and erythromycin or clindamycim, the latter being the subject of the development described in the reference. The reference discloses the use of a two-component kit which includes a container for the benzoyl peroxide and a separate container for the clindamycim. This reference does not disclose a "package" having separate containers within the package, as set forth in applicants' claims.

U.S. Patent No. 5,350,769 to Kasai et al.

This patent discloses an anti-inflammatory gel comprising an ammonium or sodium salt of diclofenac, a nonionic polymer, a dibasic ester, and a lower alcohol (there is no reference in the patent to either BP or erythromycin). The nonionic polymer functions as a gelling agent. The patent discloses specific nonionic polymeric gelling agents which are said to be capable of

forming a stable gel in a mixed solution of the dibasic ester, a lower alcohol, and water. Hydroxypropylcellulous is one of such gelling agents.

The patent discloses that an advantage of using one or more of the examplified nonionic polymers is that it permits the preparation of a composition containing a large amount of lower alcohol which helps to promote percutaneous absorption of diclofenac or its salts and to enhance the dissolution into the base components (see column 2, lines 7 to 14).

The patent makes clear that other gelling agents are not effective in forming satisfactory gels. For example, the patent discloses three comparative examples (see columns 3, 4, and 5 of the patent) which disclose the use of various gelling agents that form gels which are not stable. Accordingly, this is solid evidence that a gelling agent which functions appropriately in one environment does not necessarily function appropriately in another environment. As mentioned above, this reference does not disclose a composition which contains BP or erythromycin.

U.S. Patent No. 4,692,329 to Klein et al.

It is acknowledged that this reference discloses an acne-treating gel composition which comprises BP and erythromycin and dioctyl sodium sulfosuccinate surfactant.

Discussion of the Examiner's Rejections

With regard to the Examiner's rejection of Claims 1-17 and 36-38 as being anticipated by the Lefevre et al publication, Claims 1-17 have been canceled.

Claims 36 and 37 have been amended to depend on Claim 18 which defines subject matter that is not anticipated by the Lefevre et al. publication, as explained below.

Claim 38 has been amended to define subject matter which is not anticipated by the Lefevre et al publication. The Examiner has observed that the Lafevre et al publication refers to dispensing systems for use in the practice of their development as being exemplified in international application bearing publication number WO 97/27841. This publication, which corresponds to U.S. Patent No. 6,117,433 and which contains but a general description of a dispensing system, refers to German patent application DE 3,630,849 which corresponds to U.S. Patent No. 4,823,985, which is attached hereto as Appendix B and which discloses the details of a dispensing system.

Claim 38, as amended, distinguishes over the aforementioned '985 patent in that it recites two packets joined to one another along a commonly shared side. In contrast, the '985 patent, in Figure 1, teaches packets 2 and 3 that are contained within a common casing 4. As recited in Claim 38, the packets are foldable along the commonly shared side to bring them into facing relation adjacent to one another. There is no such folding disclosed in the '985

patent, the packets disclosed therein being in facing relation within the casing. The folding brings the tabs sealing the dispensing orifices into overlying relation allowing them to be torn off simultaneously, and also places the orifices adjacent to each other to facilitate mixing of the packet contents.

With regard to the rejection of Claims 1-7 as being anticipated by the disclosure of the Baroody et al application, as mentioned above, Claims 1-7 have been canceled.

The Examiner's rejection of Claims 18-24 and 26-28 as being obvious over the disclosure of the Lefevre et al publication in view of Kasai et al patent is traversed.

Claim 18 has been amended to define a package in which each of the BP and erythromycin components is in the form of a gel having viscosities such that, upon application of equal force to the components, there can be dispensed from the package substantially equal amounts of the components simultaneously. As discussed above, the Lefevre et al. publication discloses that the erythromycin composition is formulated as a solution. In addition, Lefevre et al. discloses that the BP composition is dispensed from the dispensing system in an amount substantially greater than the amount of the BP that is dispensed in order to dilute the erythromycin composition. Thus, Lefevre et al. discloses a delivery ratio of the BP and erythromycin compositions such that a dilution of the erythromycin composition of at least a factor of 10 is realized in the final composition (see the Lefevre et al. publication, page 6,

lines 24-29 and page 8, lines 14-16). Accordingly, applicants' claims distinguish further over the Lefevre et al. publication in reciting the delivery of substantially equal amounts of the components.

It is recognized that Lefevre et al. refer to stable erythromycin compositions in the form of a suspension, but the suspensions referred to are not gels inasmuch as they do not contain gelling agents (see the reference, page 5, lines 26-29).

With regard to the Examiner's comments concerning the relevancy of the Kasai et al. patent, as asserted above, this patent itself makes clear that gelling agents which function satisfactorily for gelling some types of materials are not necessarily effective for gelling other types of materials. Inasmuch as the materials which are disclosed in the Kasai et al patent are so significantly different from the materials defined in applicants' involved claims, it is submitted that it is not predictable and, therefore, surprising that hydroxypropylcellulose functions so effectively with applicants' claimed materials.

The disclosure of the Klein et al. patent, which is cited as a secondary reference in the other of the Examiner's §103 rejections, does not supplement the deficiencies of the disclosures of the references discussed hereinabove as regards the patentability of applicants' claims.

In view of the above, it is requested respectfully that the Examiner withdraw the §102 and §103 rejections which are the subject of the Office Action.

Miscellaneous

Enclosed herewith are copies of the publications listed on page 6 of the Information Disclosure Statement referred to on page 2 of the Action.

This Reply is accompanied by a Petition for Extension of Time to respond to the Examiner's Action.

An early and favorable Action is requested respectfully.

Respectfully submitted,
Synnestvedt & Lechner LLP

Alexis Barron, Esquire
Registration No. 22,702

2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Phone (215) 923-4466
Facsimile (215) 923-2189
abarron@synnlech.com

Aqueous Stability of Clindamycin

T. O. OESTERLING

Abstract □ The kinetics and mechanism of degradation of the antibiotic clindamycin were studied in buffered aqueous solution in the pH range 0.4–12. Clindamycin showed maximum stability at pH 3–5; however, high temperature studies indicated that not more than 10% degradation will occur in the pH range 1–6.5 after two years at 25°. In the pH range 0.4–4 the major degradative pathway was hydrolysis of the thioglycoside linkage to form 1-dethiomethyl-1-hydroxy clindamycin and methyl mercaptan. The major degradative pathway in the pH range 5–10 was scission of the 7-(S)-Cl of clindamycin to form the 7-(R)-OH analog, lincomycin. Evidence was obtained that supports the hypothesis that this conversion to lincomycin proceeds through an oxazolonium intermediate and that the extent of conversion depends on the degree of protonation of the amine function of clindamycin. The activation energy for clindamycin degradation in 0.1 *M* HCl, where thioglycoside hydrolysis is predominant, is 38.0 ± 1.2 kcal./mole, and the activation energy in 0.2 *M* citrate buffer adjusted to pH 5, where conversion to lincomycin is predominant, is 29.1 ± 0.6 kcal./mole.

Keyphrases □ Clindamycin—stability, aqueous solution □ Stability—clindamycin aqueous solutions □ Degradation, clindamycin—kinetics, mechanism, product identity □ pH effect—clindamycin stability □ Temperature effect—clindamycin stability □ GLC—analysis □ Mass spectroscopy—identity

The synthesis and biological properties of the antibiotic clindamycin (I) were first reported by Magerlein *et al.* (1, 2). Clindamycin possesses marked antiplasmodial activity (3) and is highly effective in the treatment of infections caused by Gram-positive organisms (2).



I

The purpose of this study was to investigate the degradation of clindamycin in aqueous solution in order to supply basic information necessary for the successful formulation of the drug in liquid dosage forms. The effects of pH and temperature on the rate of clindamycin degradation were studied and the major products of degradation in the pH range 0.4–12 were identified. From these data, the conditions of maximum stability of clindamycin in aqueous solution were established and the stability of clindamycin in pharmaceutical formulations could be predicted.

EXPERIMENTAL

Materials—Clindamycin, lincomycin, lincomycin tetraacetate, epilincomycin, and 7-epiclindamycin (The Upjohn Co.) were used and all other chemicals were reagent grade.



Figure 1—*Typical gas-liquid chromatogram of acetylated sample from low pH (<4) reaction mixtures. Key: Peak 1, 1-dethiomethyl-1-hydroxy clindamycin tetraacetate; Peak 2, suspected anomer of Peak 1; Peak 3, clindamycin triacetate; Peak 4, cholesteryl acetate.*

Kinetic Studies—*pH-Rate Studies*—Reaction mixtures containing clindamycin hydrochloride and buffers were prepared to cover the pH range 0.40–12 using the buffers shown in Table I. Individual buffer systems were prepared from citric acid, tartaric acid, acetic acid, succinic acid, disodium phosphate, boric acid, and sodium carbonate, and adjusted to the desired pH at 70° by the addition of hydrochloric acid or sodium hydroxide.

The concentration of clindamycin hydrochloride was 1% (0.02 *M*) in the pH range 1–6, 0.2% at pH 7, and 0.1% at pH values greater than 7. Reaction mixtures at higher pH contained less clindamycin due to the relatively low solubility of the undissociated species (about 2 mg./ml.). After preparation, volumes of each reaction mixture equivalent to 12 mg. of clindamycin hydrochloride were filled into ampuls, sealed, and placed into a 70° constant-temperature bath. At appropriate times two samples were withdrawn, the pH of one was measured, and an aliquot of the second equivalent to 10 mg. of clindamycin hydrochloride was freeze-dried. The amount of intact clindamycin present in the freeze-dried samples was determined by the gas-liquid chromatographic assay described below.

Temperature-Rate Studies—The effect of temperature on the rate of clindamycin degradation was studied in 0.1 *M* hydrochloric acid and in 0.2 *M* citrate buffer adjusted to pH 5.

Ampuls containing 10 mg./ml. of clindamycin hydrochloride in 0.1 *M* hydrochloric acid were placed into constant-temperature baths set at 47, 53, 70, 79, and 93°. At appropriate times 1.0-ml. samples were withdrawn, freeze-dried, and the amount of intact clindamycin present in the freeze-dried samples was determined by the gas-liquid chromatographic assay described below.

Ampuls containing 10 mg./ml. of clindamycin hydrochloride in the citrate buffer were placed into 47, 53, 60, 70, 80, and 90° constant-temperature baths. At appropriate times two ampuls were withdrawn, the pH of one was measured, and 1.0 ml. of the other was freeze-dried. The pH did not vary by more than 0.2 pH units from the initial pH during the reaction in all of the buffered reaction mixtures including the pH-rate studies described above. The amount of intact clindamycin present in the freeze-dried samples was determined by the gas-liquid chromatographic assay described below.

Gas-Liquid Chromatographic Assay—One milliliter of deionized water was added to the freeze-dried sample, the pH was adjusted to 11 with concentrated ammonium hydroxide, and the solution was extracted with two 1-ml. portions of ethyl acetate. The ethyl acetate extracts were combined and the solvent was removed with a stream



Figure 2—*Typical gas-liquid chromatogram of acetylated sample from high pH (5–8) reaction mixture. Key: Peak 1, clindamycin triacetate; Peak 2, suspected 7-epilincomycin tetraacetate or 7-epiclindamycin triacetate; Peak 3, lincomycin tetraacetate; Peak 4, unknown; Peak 5, cholesteryl acetate.*

of nitrogen. To the residue 1.0 ml. of a mixture of pyridine (dried over KOH)–acetic anhydride (2:1) containing 10 mg./ml. cholesteryl acetate as internal standard was added. After acetylating for 1 hr. at 100°, the solution was cooled to room temperature and 1 μl. was injected into an F & M model 402 gas chromatograph adjusted to the following conditions. Samples were partitioned between helium carrier gas flowing at 40 ml./min. and 3% OV-1 on diatomaceous earth (Gas Chrom Q) 60–80 mesh in a U-shaped glass column 120 cm. long × 3 mm. i.d. Columns were preconditioned by heating at 300° for at least 6 hr. with low helium flow and then for 1 hr. under no flow conditions. The column temperature was 220°, flash heater temperature 230°, and flame ionization detector 240°. Air and hydrogen flow rates were adjusted to give maximum response.

The concentration of clindamycin per sample was obtained by comparing clindamycin–internal standard peak height ratios to the peak height ratios of a standard curve prepared from known amounts of clindamycin. Standard curves were obtained daily.

Determination of pKa of Clindamycin at 70°—Ten milliliters of a 2.0 mg./ml. solution of clindamycin hydrochloride were titrated with 0.05 *N* NaOH in a jacketed vessel at 70° with a Radiometer TTT1C titrator and SBR2C titragraph. The average pKa of six replicate titrations was 6.90 ± 0.10.

Identification of Degradation Products—Degradation products were identified by mass spectral studies and by comparison of gas-liquid chromatographic retention times and thin layer chromatographic R_f values with authentic samples when available. Mass spectra of acetylated clindamycin and degradation products were obtained by processing acetylated reaction mixture samples through an LKB 9000 gas chromatograph-mass spectrometer and recording mass spectra of peaks of interest as they exited from the gas chromatograph column. Thin layer chromatographic studies were carried out by spotting about 50 μl. of clindamycin reaction mixtures on Silica Gel G and developing with chloroform–methanol 90:10. Spots were visualized with iodine vapor.



Figure 3—*Arrhenius plot for degradation of clindamycin in 0.1 M HCl.*

RESULTS AND DISCUSSION

Identification of Products—Gas-liquid chromatographic data indicated that the mechanism of clindamycin degradation is pH-dependent with a change in mechanism occurring in the vicinity of pH 4–5. For example, chromatograms similar to Fig. 1 were obtained from reaction mixtures whose pH was less than 4, whereas samples from reaction mixtures in the pH range 5–8 yielded chromatograms similar to the one shown in Fig. 2. The major product of degradation in the pH range 0.4–4, represented by Peak 1 in Fig. 1, had a shorter retention time than clindamycin while the major degradation product at higher pH, represented by Peak 3 of Fig. 2, had a longer retention time than clindamycin. Chromatograms from reaction mixtures at pH greater than 8 which were buffered with borate, carbonate, or NaOH showed only disappearance of clindamycin and no other peaks were observed.

The identity of the major degradation product of clindamycin at pH less than 4 was established by mass spectral studies and with a knowledge of the reactivity of lincomycin (V), the 7(R)-OH analog of clindamycin, in acid. Prescott (5) and Herr and Slomp (6) have



Scheme I

Table I—Apparent First-Order Rate Constants of Degradation of Clindamycin

pH	Buffer	Temperature, °C.	k, sec.$^{-1}$ × 10^{-6}
0.44[a]	0.5 *M* HCl	70	19.0
0.54[a]	0.4 *M* HCl	70	19.3
0.66[a]	0.3 *M* HCl	70	14.3
0.83[a]	0.2 *M* HCl	70	8.25
1.10[a]	0.1 *M* HCl	70	4.50
1.10[a]	0.1 *M* HCl	70	4.66
1.10[a]	0.1 *M* HCl	47	0.0199
1.10[a]	0.1 *M* HCl	53	0.252
1.10[a]	0.1 *M* HCl	59	1.43
1.11[a]	0.1 *M* HCl	79	13.0
1.11[a]	0.1 *M* HCl	93	66.5
1.94	0.2 *M* Citrate	70	0.831
1.95	0.2 *M* Citrate	70	0.805
2.90	0.2 *M* Citrate	70	0.295
2.95	0.2 *M* Citrate	70	0.318
3.92	0.2 *M* Citrate	70	0.243
4.00	0.2 *M* Citrate	70	0.249
4.07	0.2 *M* Citrate	70	0.242
4.00	0.2 *M* Citrate	47	0.0124
4.00	0.2 *M* Citrate	53	0.0279
4.00	0.2 *M* Citrate	59	0.0831
4.00	0.2 *M* Citrate	80	0.969
4.00	0.2 *M* Citrate	92	3.62
4.80	0.2 *M* Tartrate	70	0.276
4.85	0.2 *M* Acetate	70	0.278
5.00	0.2 *M* Succinate	70	0.280
5.00	0.2 *M* Citrate	70	0.276
5.95	0.2 *M* Citrate	70	0.665
6.00	0.2 *M* Phosphate	70	0.620
6.00	0.2 *M* Citrate	70	0.946
6.90	0.2 *M* Citrate	70	2.07
6.95	0.2 *M* Citrate	70	2.89
7.25	0.2 *M* Phosphate	70	4.00
7.85	0.2 *M* Phosphate	70	5.91
8.20	0.2 *M* Phosphate	70	4.08
8.30	0.2 *M* Phosphate	70	7.11
8.50	0.2 *M* Borate	70	15.2
9.30	0.2 *M* Borate	70	15.5
9.50	0.2 *M* Borate	70	16.7
9.70	0.2 *M* Borate	70	17.7
9.75	0.2 *M* Borate	70	14.9
10.00	0.2 *M* Borate	70	29.9
11.00	0.2 *M* Carbonate	70	149
11.66[b]	0.1 *M* NaOH	70	204

[a] Calculated from pH = − Log f(HCl): where (HCl) is the experimental molarity and f is the mean activity coefficient for HCl at 70° extrapolated from the literature (4). [b] Calculated from pH = pKw − pOH: where pKw = 12.77 at 70° (4), pOH = − Log f(NaOH), (NaOH) is the experimental molarity, and f is the mean activity coefficient for NaOH extrapolated from the literature (4).

reported that lincomycin (V) degrades in acid *via* thioglycoside hydrolysis to form *1*-dethiomethyl-*1*-hydroxylincomycin and methyl mercaptan. Clindamycin might be expected to react in acid in a manner similar to lincomycin and mass spectral data indicate that the molecular weight of the compound represented by Peak 1 of Fig. 1 is 562. This molecular weight corresponds to acetylated *1*-dethiomethyl-*1*-hydroxyclindamycin which indicates that II in Scheme I is the major product of clindamycin degradation at pH less than 4.

II can be detected gas chromatographically as the predominant reaction product for about three clindamycin half-lives after which it begins to disappear. The decrease in magnitude of the gas-liquid chromatographic peaks of II and clindamycin at extended reaction times is accompanied by the appearance of several small peaks of shorter retention time. This further degradation may result from breakdown of the sugar moiety or amide hydrolysis (6).

Peak 2 of Fig. 1 represents another product of clindamycin degradation at pH less than 4 which is present in the early stages of the reaction. As the reaction proceeds, Peak 2 behaves similarly to Peak 1 and decreases in magnitude after about three clindamycin half-lives. Since thioglycoside hydrolysis proceeds through a carbonium ion intermediate (7), the products of clindamycin would be methyl mercaptan and an anomeric mixture of II. Mass spectral studies indicated that Peak 1 represents one of the anomers and



Figure 4—*Arrhenius plot of clindamycin degradation at pH 4 in 0.2* M *citrate buffer.*

Peak 2 may represent the other. The identification of Peak 2 was not attempted.

Lincomycin (V) was identified as the major degradation product of clindamycin at pH greater than 5. Mass spectral studies of Peak 3 of Fig. 2 showed that the molecular weight of this compound was 574, the molecular weight of acetylated lincomycin. Further, the gas-liquid chromatographic retention time of Peak 3 of Fig. 2 is identical to authentic lincomycin tetraacetate. Lincomycin, as well as clindamycin, is unstable in the pH range 5–8 as both Peaks 1 and 3 of Fig. 2 disappear at long reaction times. One possible route of degradation of lincomycin and clindamycin at extended reaction times is amide hydrolysis.

It is obvious from Fig. 2 that lincomycin is not the sole product of clindamycin degradation at pH 5–8. At least two other reaction products are represented by Peaks 2 and 4 of Fig. 2. Both Peaks 2 and 4 represent minor products and neither was ever present in



Figure 5—*Apparent first-order disappearance of clindamycin in 0.1* M *HCl at various temperatures. Key:* ○ *47°,* □ *53°,* △ *59°,* ● *69°.*



Figure 6—*pH-Rate profile of clindamycin degradation at 70°.*

amounts greater than that shown in Fig. 2. Peak 2 may represent acetylated 7-epilincomycin or acetylated 7-epiclindamycin since its retention time was identical to authentic samples of each. Magerlein has reported the formation of a trace of 7-epilincomycin after refluxing an aqueous solution of clindamycin at pH 7.8 (8). Peak 4 of Fig. 2 was not identified.

Although lincomycin (V) and Peaks 2 and 4 of Fig. 2 could not be detected above pH 8 by GLC, TLC of these reaction mixtures indicated that some of these degradation products were present but were not being extracted for gas chromatographic assay. Thin layer chromatograms of the reaction mixtures above pH 8 showed clindamycin and lincomycin by comparison with authentic samples and three other spots which were not identified. Gas chromatograms of reaction mixtures below pH 8 showed that the major degradation products were extracted by ethyl acetate. The sum of the moles of acetylated IV (Scheme I) and clindamycin between pH 5 and 8 and of acetylated II and clindamycin below pH 5 was greater than 90% of the initial clindamycin concentration in the early stages of the reaction.

Temperature-Rate Studies—Arrhenius plots of clindamycin degradation in 0.1 *M* HCl and at pH 4 are shown in Figs. 3 and 4. The activation energy for clindamycin degradation in 0.1 *M* HCl was calculated to be 38.0 ± 1.2 kcal./mole. The principal degradative pathway in 0.1 *M* HCl is hydrolysis of the *1*-thio-α-D-galactopyranoside moiety of clindamycin at Position 1 to form *1*-dethio-*1*-hydroxy-clindamycin (II) and methyl mercaptan (Scheme I). The activation energy for clindamycin degradation in 0.1 *M* HCl falls in the 30–38 kcal./mole range reported by other investigators for acid degradation of compounds of similar structure such as alkyl *1*-thio-β-D-glucopyranosides (9), alkyl β-D-xylopyranosides (10), and alkyl α- and β-D-glucopyranosides (11).

The activation energy for clindamycin degradation at pH 5, the pH of maximum stability, was calculated to be 29.1 ± 0.6 kcal./mole. Using the rate constants in Table I and the appropriate activation energy, the prediction can be made that clindamycin in pharmaceutical formulations adjusted to pH 1–6.5 will not degrade by more than 10% after 2 years at 25°.

pH-Rate Studies—Clindamycin disappeared from reaction mixtures by an apparent first-order process under all of the conditions studied. Some typical log clindamycin concentration-time curves are shown in Fig. 5.

The effect of pH on the rate of clindamycin degradation in the pH range 0.40–12 at 70° is shown in Fig. 6.

Different buffer species did not appear to significantly influence the rate of degradation since a continuous curve was obtained for the pH profile and since the rate constant did not vary with different buffers at the same pH (Table I).

The pH profile of clindamycin (Fig. 6) shows that the rate of degradation increases with decreasing pH in the pH range 0.4–4. This is expected since both major degradative routes in this pH region, thioglycoside and amide hydrolysis, are susceptible to hydrogen ion catalysis. Being of similar structure, lincomycin (V) should also degrade by these two routes in acid media and the rate constant should agree with that of clindamycin when reacted under similar conditions. Forist, *et al.* (12) studied the degradation of V in 0.1 *N* HCl at 70° and the rate constant of 4.85 × 10^{-6} sec.$^{-1}$ calculated from their data agrees quite favorably with the clindamycin values in Table I.

In the pH range 5–12 the degradative rate increases with increasing pH with an inflection point in the pH 9–10 region. GLC and TLC of reaction mixtures in this pH region show that at least four products are formed by clindamycin degradation. The times of appearance of the various products and their relative concentrations indicate parallel reactions. Assuming there are parallel reactions occurring, the shape of the pH-rate profile in Fig. 6 in the pH 4–12 region might be interpreted as follows. In the pH 4–9 region all degradative rates are increasing with increasing pH with one of the reactions predominating. Above pH 9 the rate constant of the reaction which was predominating at pH 5–9 becomes constant but the rates of the other reactions continue to increase with increasing pH.

Gas-liquid and thin layer chromatographic data of this study show that the predominant degradative reaction at pH 5–9 is conversion to lincomycin (V). Results of studies by Magerlein (8, 13) show how the rate of lincomycin conversion could be predominant in this pH range and then become constant above pH 9. Magerlein has postulated that conversion to lincomycin occurs through the oxazolonium ion intermediate (VII) shown in Scheme II and that the extent of conversion is highly dependent on the participating ability of the substituent on the amide carbonyl (13). For example, solvolysis is anchimerically assisted by the neighboring amide carbonyl if the carbonyl substituent is methyl, whereas when R_1 is a strong electron withdrawing group such as trifluoromethyl, participation does not occur. Magerlein also reports that the 7(S)-Cl position of clindamycin is resistant to direct S_N2 nucleophilic displacement (8).



Scheme II

In the present study no conversion to lincomycin was observed at pH values less than 5, whereas lincomycin was detected by GLC or TLC in all reaction mixtures buffered to pH values greater than 5. Assuming that the protonated form of the *N*-methyl-4-propylpyrrolidine portion of clindamycin (R_1) is analogous to trifluoromethyl as a nonparticipating substituent and $k_1 \ll k_2$, no conversion to lincomycin would be expected in the pH range where R_1 is fully protonated, *i.e.*, at pH values less than 5. On the other hand, it is possible that lincomycin can be detected in the pH 5 reaction mixtures because the small amount of nonprotonated R_1 has facilitated conversion to lincomycin and the increase in rate of clindamycin degradation is partly due to this reaction. As the pH increases the rate of conversion to lincomycin increases due to the presence of more nonprotonated R_1. The leveling trend in the pH profile at pH 9, two pH units above the pKa of 6.90, might be due to a constant rate of lincomycin conversion since at pH 9 and above all of R_1 exists in the nonprotonated form. The further increase in overall rate above pH 10 might then be due to an increase in the rate of other reactions such as amide hydrolysis.

The relationship between pH and the mechanism of clindamycin degradation could be summed as follows. Below pH 4 clindamycin degrades *via* thioglycoside and amide hydrolysis with thioglycoside hydrolysis predominant in the pH range 0.4–4. Above pH 5 clindamycin degrades by conversion to lincomycin and by other reactions such as amide hydrolysis. The extent of lincomycin conversion is dependent on the degree of protonation of the *N*-methyl-4-propylpyrrolidine moiety. At pH less than 5 where the amine is fully protonated no conversion to lincomycin occurs. Then this process can be detected in the vicinity of pH 5 and its rate increases as pH increases to pH 9 and then becomes constant since the amine function is completely nonprotonated. The overall rate of clindamycin degradation continues to increase with increasing pH above pH 9, however, due to the hydroxide ion dependency of the other degradative routes.

REFERENCES

(1) R. D. Birkenmeyer, Abstracts of Papers, Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy and IV International Congress of Chemotherapy, Washington, D. C., October 17–21, 1965.

(2) B. J. Magerlein, R. D. Birkenmeyer, and F. Kagan, *Antimicrobial Agents Chemotherapy*, 1966, 727.

(3) C. Lewis, *J. Parasitol.*, 54, 169(1968).

(4) H. S. Harned and B. B. Owen, "The Physical Chemistry of Electrolyte Solutions," Reinhold, New York, N. Y., 1958.

(5) G. C. Prescott, *J. Pharm. Sci.*, 55, 423(1966).

(6) R. R. Herr and G. Slomp, *J. Am. Chem. Soc.*, 89, 2444(1967).

(7) J. N. Be Miller, in "Advances in Carbohydrate Chemistry," vol. 22, M. L. Wolfrom and R. S. Tipson, Eds., Academic, New York, N. Y., 1967, p. 25 ff.

(8) B. J. Magerlein, "Chemical Modifications of Lincomycin," Medicinal Chemistry Symposium, Quebec, Canada, June 23–26, 1968.

(9) M. D. Saunders and T. E. Timell, *Carbohydrate Res.*, 6, 121(1968).

(10) C. K. De Bruyne and F. Van Wijnendaele, *ibid.*, 6, 367 (1968).

(11) T. E. Timell, *Can. J. Chem.*, 42, 1456(1964).

(12) A. A. Forist, L. W. Brown, and M. E. Royer, *J. Pharm. Sci.*, 54, 476(1965).

(13) B. J. Magerlein and F. Kagan, *J. Med. Chem.* (in press).

ACKNOWLEDGMENTS AND ADDRESSES

Received June 4, 1969 from the *Research Laboratories, The Upjohn Company, Kalamazoo, MI 49001*

Accepted for publication August 28, 1969.

Presented to the Basic Pharmaceutics Section of the APhA Academy of Pharmaceutical Sciences, Montreal meeting, May 1969.

The author wishes to thank Dr. P. B. Bowman for obtaining and aiding in the interpretation of mass spectra, and Mr. G. R. Munting for excellent technical assistance in this work.

Coumarins XI: A Total Synthesis of (±)-Columbianetin

M. SHIPCHANDLER*, T. O. SOINE†, and P. K. GUPTA

Abstract □ (±)-Columbianetin [(±)-I] has been synthesized by a ten-step sequence starting with 2,6-dihydroxybenzoic acid which was converted to the methyl ester, benzylated, and reduced to the benzyl alcohol which was oxidized to the aldehyde and monodebenzylated to provide 2-hydroxy-6-benzyloxybenzaldehyde (VI). Treatment of VI with methyl bromoacetate converted it to methyl 3-benzyloxy-2-formylphenoxyacetate which was cyclized to methyl 4-benzyloxybenzofuran-2-carboxylate, the latter being converted to 2-(α-hydroxyisopropyl)-4-benzyloxybenzofuran (XIV) by the action of CH_3MgI. Reduction and debenzylation of XIV to the corresponding dihydrobenzofuran followed by acid-catalyzed condensation with ethyl propiolate provided (±)-I.

Keyphrases □ (±)-Columbianetin—total synthesis □ TLC—separation identity □ Mass spectroscopy—identity □ UV spectrophotometry—identity □ IR spectrophotometry—identity □ NMR spectroscopy—identity

The isolation of two new coumarins from the umbellifer, *Lomatium columbianum* Math. and Const., was reported in 1964 (1). One of these coumarins, a glycoside assigned the name columbianin, has since been shown to occur in *L. dissectum* var. *multifidum* (Nutt.) Math. and Const. (2) and *L. nuttallii* (A. Gray) Macbr. (3). Acid hydrolysis of columbianin yielded D-glucose and a tertiary coumarinic aglycone, columbianetin (I) and led to the postulation of II as the structure for the glycoside. More recent studies (4) have revised the structure to III, *i.e.*, the β-D-gentiobioside of I (III). The other coumarin, columbianadin, was assigned Structure IV, *i.e.*, the angelate ester of I, and has been found in *Peucedanum palustre* (5) as well as in *Zosimia absinthifolia* (Vent.) Link (6, 7). The absolute configuration of I has been shown to be 8(S) (8).



I, R = H

II, R = D-Glucosyl

III, R = β-D-Gentiobiosyl

IV, R = Angeloyl



V

The recent total synthesis of marmesin (V) and its optical antipode, nodakenetin, by Nakajima *et al.* (9) and confirmed by Harada *et al.* (10) in a study of the absolute configuration suggested that a similar synthesis could be applied to the preparation of I by utilizing 2-hydroxy-6-benzyloxybenzaldehyde (VI) as starting material in place of the isomeric 2-hydroxy-4-benzyloxybenzaldehyde employed by these workers. The preparation of VI from 2,6-dihydroxybenzaldehyde (*i.e.*, γ-resorcylaldehyde) was the obvious route but a survey of the literature pertaining to the preparation of the latter (11–15) indicated that all of the published methods were characterized by poor overall yields as well as lengthy synthetic sequences. Thus, a synthesis of